Trial Profile
A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Apr 2014
Price :
$35
*
At a glance
- Drugs E 2212 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eisai Co Ltd; Eisai Inc
- 07 Feb 2013 Actual end date changed from Mar 2012 to Nov 2012 as reported by ClinicalTrials.gov.
- 20 Oct 2010 New trial record